Conditions: Myelodysplastic Syndromes
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1
Healthy volunteers: no

Brief summary:
The objectives of this trial are to evaluate the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics and preliminary efficacy of volasertib in two dosing schedules of intravenous volasertib as monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome (MDS) after hypomethylating agents (HMA) treatment failure.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Volasertib intervention 2: Volasertib intervention 3: Azacitidine
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None

Protocol document: